NCT06961357View on ClinicalTrials.gov

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2030

Conditions
Melanoma
Interventions
DRUG

Cyclophosphamide

Part of lymphodepletion regimen.

DRUG

Fludarabine

Part of lymphodepletion regimen.

DRUG

Interleukin-2

Standard of care.

DRUG

TIL Product

Tumor-infiltrating lymphocytes are an investigational, personalized adoptive cell therapy.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT06961357 - Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | Biotech Hunter | Biotech Hunter